Launching New Oncology and Hematology Therapies
Commercializing new therapies is extremely complex, crowded and chaotic, but successful launches are essential for patients in the fight against cancer. Manufacturers of new, high-science brands are often faced with:
- Unprecedented pressure to accelerate their speed to market,
- Securing patient access and affordability, and
- Creating compelling stakeholder engagement in a hybrid world.
The first five years of commercialization typically costs $265M. Manufacturers should not be forced to lose ownership, sacrifice their company value or invest more than $200M to commercialize on their own. Instead, they must decide how to develop the necessary infrastructure for launch, shape the market and build industry relationships.
Therapy and Tumor Types Drive Launch Strategies
Unlike traditional launch plans designed for blockbuster products, oncology and hematology drug commercialization requires agility. Different tumor types and the form of therapy require distinct commercialization strategies. Patients with lung cancer, breast cancer or colon cancer, for example, can be found through screening and may have multiple lines of therapy over multiple years so their needs in patient services and financial assistance are much different than for patients with pancreatic cancer, who are frequently diagnosed at a late stage and may have acute needs. At EVERSANA, we developed an innovative commercialization model specific to product and patient needs using a system of archetypes that consider therapy type, how the product is administered and the impact of the therapy on the patient journey.
Leveraging our award-winning model commercialization model, coupled with our deep bench of experts, EVERSANA partners with manufacturers to develop a customized, comprehensive go-to-market strategy. Click here to learn more.